Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Karam on the Role of Debulking Surgery in Recurrent Ovarian Cancer

January 28th 2022

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Minimally Invasive Surgery Could Benefit Patients with Advanced Ovarian Cancer

January 28th 2022

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

Starting Maintenance Therapy for Ovarian Cancer

January 27th 2022

Robert W. Holloway, MD, details how he decides to start maintenance therapy after first-line ovarian cancer treatments.

Case Scenario: Stage 3A High-Grade Epithelial Ovarian Cancer

January 27th 2022

Chad A. Hamilton, MD, and Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer.

FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations

January 25th 2022

The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.

Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian Cancer

January 24th 2022

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

Genetic Counseling for Ovarian Cancer

January 20th 2022

Oncologists debate the need for genetic counseling for ovarian cancer patients and how to approach molecular testing alongside neoadjuvant chemotherapy.

Sequencing of Biomarker Testing for Ovarian Cancer

January 20th 2022

Dr Robert W. Holloway explains his typical approach to ovarian cancer biomarker testing and sequencing.

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

January 18th 2022

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer.

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7th 2022

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers

January 6th 2022

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Dr. Monk on the Emergence of NaPi2b as a Target in Ovarian Cancer

January 5th 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer

January 4th 2022

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

HRD Status Drives Decisions With Frontline PARP Inhibition in Advanced Ovarian Cancer

January 4th 2022

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Molecular Testing and Ovarian Cancer

December 22nd 2021

Chad A. Hamilton, MD, and Robert W. Holloway, MD, discuss challenges clinicians face in treating ovarian cancer and review the current state of biomarker testing.

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

December 17th 2021

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

December 17th 2021

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian Cancer

December 7th 2021

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer. 

Dr. Rose on the Importance of Genetic Testing in Ovarian Cancer

December 2nd 2021

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer

December 2nd 2021

Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer.